How to process IVIG for a new patient?

To access current national guidance follow link:
https://igd.mdsas.com/clinical-info/

Commissioning criteria.
All conditions for which IVIG is commissioned by NHSE are included in "Commissioning Criteria Policy for the use of therapeutic immunoglobulin (Ig) England, 2021" (follow link above). Refer also to the "Department of Health and Social Care (DHSC) 2011 clinical guidelines for immunoglobulin use" for those indications that have not moved into routine commissioning. For all other indications or clinical scenarios IVIG is **not** routinely commissioned and so requires an Individual Funding Request (IFR) application to be submitted to the national IFR panel. The application may only be made if prior support has been given by the local SRIAP. If approved then



Choice of product

*Intermittent shortages will influence Trust allocations and so adaptation to the below may occur to use up reserve stocks. Pharmacy staff will be informed of this as will influence use of products in one-off acute indications and EDC stock.

*Reserve the use of "Privigen" for one-off acute indications, existing long-term patients, new long-term indications only'

* Reserve the use of "Intratect", "FlebogammaDif" and "Octagam" for existing long-term patients only.

* If a specific brand is specified for a new patient, determine whether this is due to a lack of tolerability to other products (often after assessment at a tertiary centre) and keep to brand prescribed.

* Patients transferred to the Trust on an existing product will require their prescription to be reviewed and either product changed or arrangements made for their originating Trust allocation be transferred.

* Patients should be dosed according to their body weight adjusted for IVIG dosing weight
https://ivig.transfusionontario.org/dose/

SRIAP applications (panel referrals)

All applications must be made through the Panel Referrals functionaly within the MDSAS database

Applications for neurology and haematology specialities will be made directly by clinicians (usually the consultant involved in the care of the patient).

Applications for other specialities will be made through the supporting structure of the clinical pharmacy support service to the ward area affected and /or speciality.
Please use the adapted UHB SRIAP application form to support completion.
IG Database – igd (mdsas.com)

M:\Acute\Pharmacy\Countywide\IVIG\

Access to IVIG supplies out of hours
- Stock of "Privigen" (or alternative as above) is held in the Emergency Drug Cupboards at WRH and AH
- Stock should only be taken after approval by the on-call pharmacist (OCP)
- Details of the patient, condition being treated for and that supply may be made without SRIAP prior approval to be given to the OCP and recorded appropriately in the EDC record
- On-call pharmacist to inform the appropriate clinical pharmacy team lead to ensure that that the retrospective SRIAP application is completed
- EDC stocks will be replenished by pharmacy on the following working day - should stock

Role of the SRIAP
All Provider Trusts that use human normal immunoglobulin (IVIG) are required to participate in a hub and spoke model where approval is required for all IVIG use by the Sub Regional Immunoglobulin Advisory Panel (SRIAP). The local panel for Worcestershire Acute Hospitals Trust is the West Midlands South/Central SRIAP hosted by University Hospitals Birmingham NHS Trust (UHB). The SRIAP has responsibilty for managing individual patient access to IVIG including review of eligibilty, indications, dose